XL 888

Drug Profile

XL 888

Alternative Names: EXEL-4888; Heat Shock Protein 90 Inhibitor XL888; Hsp90 Inhibitor XL888; XL888

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Exelixis
  • Developer Emory University; Exelixis; H. Lee Moffitt Cancer Center and Research Institute; Merck Sharp & Dohme
  • Class Antineoplastics; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Gastrointestinal cancer; Malignant melanoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Late-stage disease) in USA (PO)
  • 28 Jun 2017 Phase-I clinical trials in Gastrointestinal cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (PO) (NCT03095781)
  • 03 Apr 2017 Emory University, Merck Sharp & Dohme and Exelixis plan a phase I trial for Gastrointestinal cancer (Late-stage disease, Combination therapy, Inoperable/unresectable, Metastatic disease, Second-line therapy or greater) in USA (NCT03095781)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top